Company
Every investor coverage indicates participated in a round Finn Partners raised.
Companies Finn Partners acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Finn Partners. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon Capital reports that ENA Respiratory has become the first Australian company chosen for BLUE KNIGHT, a JLABS-BARDA initiative supporting its intranasal broad-spectrum antiviral spray INNA-051.
ENA Respiratory has begun a Phase 2a influenza-challenge trial in the UK of its INNA-051 antiviral nasal spray; the article also recalls its Series A backing by Brandon Capital, Minderoo Foundation and Uniseed.
Biotech firm ENA Respiratory has contracted PPD and hVIVO to run Phase 2 trials of its INNA-051 nasal spray, which aims to prevent COVID-19 and other respiratory viral infections, after encouraging Phase 1 safety results.